Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.67 USD | -8.56% | -15.51% | -69.62% |
Financials (USD)
Sales 2024 * | 278M | Sales 2025 * | 372M | Capitalization | 279M |
---|---|---|---|---|---|
Net income 2024 * | -190M | Net income 2025 * | -89M | EV / Sales 2024 * | 1.82 x |
Net Debt 2024 * | 226M | Net Debt 2025 * | 224M | EV / Sales 2025 * | 1.35 x |
P/E ratio 2024 * |
-1.38
x | P/E ratio 2025 * |
-3.01
x | Employees | 597 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Revance Therapeutics, Inc.
1 day | -8.56% | ||
1 week | -15.51% | ||
Current month | -26.04% | ||
1 month | -27.05% | ||
3 months | -51.37% | ||
6 months | -63.37% | ||
Current year | -69.62% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.06% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 2.67 | -8.56% | 3,000,357 |
24-05-22 | 2.92 | -2.99% | 1,919,859 |
24-05-21 | 3.01 | -4.75% | 1,885,209 |
24-05-20 | 3.16 | +4.64% | 2,471,630 |
24-05-17 | 3.02 | -4.43% | 2,197,279 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.62% | 279M | |
-2.00% | 90.27B | |
+1.32% | 40.12B | |
-15.73% | 31.75B | |
+64.13% | 26.6B | |
-21.28% | 14.41B | |
-8.50% | 12.92B | |
-44.07% | 11.3B | |
-13.06% | 11.44B | |
+4.94% | 8.87B |
- Stock Market
- Equities
- RVNC Stock